Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OCTRU have now given Green Light approval for The World Hip Trauma Evaluation (WHiTE) Platform and its first embedded randomised comparison WHiTE 11 FRUITI: Fix or Replace Undisplaced Intracapsular fractures Trial of Interventions, which is now open to recruitment. The WHiTE Platform is a clinical trials framework designed to efficiently deliver multiple randomised comparisons of interventions for fragility hip fracture in those aged 60 and over. The FRUITI comparison aims to determine whether there is a difference in health-related quality of life at four months after surgery in patients with undisplaced intracapsular fractures treated with internal fixation or hip replacement.

 Follow on Twitter! @WHiTEPlatform  @WHiTE11FRUITI


Similar stories

Going straight to surgery found to be better than undergoing rehabilitation first for longstanding anterior cruciate ligament injury

New research, funded by the National Institute for Health and Care Research (NIHR), shows initial surgery to be more successful and cost effective than undergoing treatment with rehabilitation first to treat longstanding anterior cruciate ligament injury.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Emergency departments to use the FORCE pathway for wrist fractures in children

New research from the University of Oxford has shown that doctors can simplify treatment for the most common fracture in children, reducing NHS costs.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.